If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Production and secretion === Secretin is synthesized in cytoplasmic secretory granules of S cells, which are found mainly in the mucosa of the duodenum, and in smaller numbers in the jejunum of the small intestine. Secretin is released into circulation and/or intestinal lumen in response to low duodenal pH that ranges between 2 and 4.5 depending on species; the acidity is due to hydrochloric acid in the chyme that enters the duodenum from the stomach via the pyloric sphincter. Also, the secretion of secretin is increased by the products of protein digestion bathing the mucosa of the upper small intestine. Secretin release is inhibited by H2 antagonists, which reduce gastric acid secretion. As a result, if the pH in the duodenum increases above 4.5, secretin cannot be released.
In the mid-1960s, Owsley Stanley, the most important black market LSD manufacturer in the United States, distributed LSD at a standard concentration of 270 μg, while street samples of the 1970s contained 30 to 300 μg. By the 1980s, the amount had reduced to between 100 and 125 μg, dropping more in the 1990s to the 20 to 80 μg range, and even further in the 2000s.
=== 2010 census === The 2010 United States census counted 8,573 people, 3,002 households, and 2,318 families in the borough. The population density was 4,154.5 per square mile (1,604.1/km2). There were 3,114 housing units at an average density of 1,509.0 per square mile (582.6/km2). The racial makeup was 68.95% (5,911) White, 0.73% (63) Black or African American, 0.03% (3) Native American, 27.64% (2,370) Asian, 0.01% (1) Pacific Islander, 1.07% (92) from other races, and 1.55% (133) from two or more races. Hispanic or Latino of any race were 6.26% (537) of the population. Korean Americans accounted for 17.8% of the population. Of the 3,002 households, 40.5% had children under the age of 18; 66.2% were married couples living together; 7.9% had a female householder with no husband present and 22.8% were non-families. Of all households, 21.1% were made up of individuals and 15.4% had someone living alone who was 65 years of age or older. The average household size was 2.84 and the average family size was 3.32. Same-sex couples headed 7 households in 2010, an increase from the 5 counted in 2000. 26.8% of the population were under the age of 18, 5.4% from 18 to 24, 20.6% from 25 to 44, 29.8% from 45 to 64, and 17.4% who were 65 years of age or older. The median age was 43.7 years. For every 100 females, the population had 88.6 males. For every 100 females ages 18 and older there were 85.7 males.
Jaw joint – The dentary (the lower jaw bone, which carries the teeth) and the squamosal (a small cranial bone) meet to form the joint. In most gnathostomes, including early therapsids, the joint consists of the articular (a small bone at the back of the lower jaw) and quadrate (a small bone at the back of the upper jaw). Middle ear – In crown-group mammals, sound is carried from the eardrum by a chain of three bones, the malleus, the incus and the stapes. Ancestrally, the malleus and the incus are derived from the articular and the quadrate bones that constituted the jaw joint of early therapsids. Tooth replacement – Teeth can be replaced once (diphyodonty) or (as in toothed whales and murid rodents) not at all (monophyodonty). Elephants, manatees, and kangaroos continually grow new teeth throughout their life (polyphyodonty). Prismatic enamel – The enamel coating on the surface of a tooth consists of prisms, solid, rod-like structures extending from the dentin to the tooth's surface. Occipital condyles – Two knobs at the base of the skull fit into the topmost neck vertebra; most other tetrapods, in contrast, have only one such knob. For the most part, these characteristics were not present in the Triassic ancestors of the mammals. Nearly all mammaliaforms possess an epipubic bone, the exception being modern placentals.
Sources: en.wikipedia.org
Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist. Terlipressin was approved for medical use in the United States in 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Another important piece of evidence is from detailed phylogenetic trees (i.e., "genealogic trees" of species) mapping out the proposed divisions and common ancestors of all living species. In 2010, Douglas L. Theobald published a statistical analysis of available genetic data, mapping them to phylogenetic trees, that gave "strong quantitative support, by a formal test, for the unity of life." Traditionally, these trees have been built using morphological methods, such as appearance, embryology, etc. Recently, it has been possible to construct these trees using molecular data, based on similarities and differences between genetic and protein sequences. All these methods produce essentially similar results, even though most genetic variation has no influence over external morphology. That phylogenetic trees based on different types of information agree with each other is strong evidence of a real underlying common descent.
Negotiations to buy 30 TriStars of the L-1011-385-250 version and licence-produce up to 100 a year in a new factory employing 80,000 people continued until mid-1976. Any residual will to export TriStars was scotched when administration of US President Jimmy Carter made human rights a key pillar of US foreign policy. TriStar exports would have needed Coordinating Committee clearance: the type embodied advanced technology banned from potential enemies. In 1978, the US Department of Commerce vetoed export of 12 General Electric CF6-50 engines ordered by the USSR for planned long-range Il-86s. By analogy with other aircraft programmes, a third direction in the efforts to acquire foreign technology may have involved illicit action along the lines of the reverse engineering of the Tu-4 from the B-29 and the copying of the Rolls-Royce Nene jet engine as the Klimov VK-1. Oblique reference to this comes in an account of the An-124 by the then-powerplant head of the Antonov bureau, V. G. Anisyenko: "The MAP leadership wanted to have a uniform large engine also capable of civil aviation applications, such as the Il-86. The most suitable analogue from this viewpoint was considered to be the Rolls-Royce RB.211-22. To purchase it, in 1976 a MAP procurement party went to Great Britain, headed by engine construction deputy minister Dondukov ... Our ultimate task was to copy the RB.211-22, for which purpose we had to buy not fewer than eight examples ... The English ... would only sell us the engine in quantities ... to power no fewer than 100 aircraft.
=== Interactions === When two or more vaccines are mixed in the same formulation, the two vaccines can interfere. This most frequently occurs with live attenuated vaccines, where one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was noted in the trivalent Sabin polio vaccine, where the relative amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype 1 and 3 viruses in the vaccine. To accomplish this, the doses of serotypes 1 and 3 were increased in the vaccine in the early 1960s. It was also noted in a 2001 study to be a problem with dengue vaccines, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, -2 and -4 serotypes.
== Receptors == The major cell-matrix adhesion receptors are integrins and therefore the adhesome of cell-matrix adhesion is referred to as the integrin adhesome. Cell-cell adhesion is primarily mediated by cadherin receptors and therefore the adhesome of cell-cell adhesion is referred to as the cadherin adhesome or cadhesome. The first attempts to establish the set of proteins that participate directly ('bona fide' adhesome components) or affect indirectly ('associated' adhesome components) cell adhesion were based on mining of the primary research literature, and resulted in approximately 200 protein in either integrin or cadherin adhesomes. Later, unbiased proteomic approaches utilizing mass spectrometry have detected hundreds more proteins associated with integrin adhesions. However, a comparison of multiple proteomic studies of the integrin adhesome of fibroblasts attached to fibronectin found only 60 proteins common to all studies.
Sources: en.wikipedia.org
Wolpaw and Pinkerton turned down invitations to return to Valve early in the Alyx development. Instead, Valve recruited Rob Yescombe of The Invisible Hours, who worked on Alyx in 2017 and 2018. Yescombe's narrative was darker than previous Half-Life games, with scenes of dread, torture and horror. The antagonist was a female Combine officer named Hahn; in one proposed ending, Alyx would kill Hahn in revenge for torturing her father. Yescombe also proposed an ending in which Alyx and the G-Man would travel back in time to the events of the first Half-Life to prevent Freeman from triggering the alien invasion. After the company-wide playtest in 2018, feedback was overwhelmingly positive save for the story, which employees scored the lowest of any Valve game. Morasky described it as "dark, serious and laborious", likening it to a Zack Snyder superhero film. The designer Corey Peters said the feedback vindicated their misgivings. Valve initially planned to launch Alyx alongside its Index VR headset in June 2019, but delayed it to address the story. They re-enlisted Wolpaw and Pinkerton to rewrite the plot and dialogue while preserving the gameplay, along with Jake Rodkin and Sean Vanaman, who had joined when Valve acquired Campo Santo. Laidlaw, who retired in 2016, denied reports that he had provided consultation, saying he had confidence in Pinkerton and Wolpaw and that he did not want them "second-guessing" him. The new writing team identified three problems. First, the nature of a prequel meant that players knew the characters would survive, reducing suspense.
Growth hormone secretagogue receptor(GHS-R), also known as ghrelin receptor, is a G protein-coupled receptor that binds growth hormone secretagogues (GHSs), such as ghrelin, the "hunger hormone". The role of GHS-R is thought to be in regulating energy homeostasis and body weight. In the brain, they are most highly expressed in the hypothalamus, specifically the ventromedial nucleus and arcuate nucleus. GSH-Rs are also expressed in other areas of the brain, including the ventral tegmental area, hippocampus, and substantia nigra. Outside the central nervous system, too, GHS-Rs are also found in the liver, in skeletal muscle, and even in the heart.
An international organization, also known as an international institution or intergovernmental organization (IGO), is an association of states established by a treaty or other type of instrument governed by international law to pursue the common aim of its member states. An IGO possesses its own legal personality separate from its member states and can enter into legally binding agreements with other IGOs or with other states. The United Nations (UN), the Council of Europe, the African Union, the Organization of American States (OAS), the North Atlantic Treaty Organization (NATO), Mercosur, and BRICS are examples of IGOs. International organizations are composed of primarily member states, but may also include other entities, such as other international organizations, commercial firms, and nongovernmental organizations. Additionally, entities may hold observer status. Under international law, although treaties are typically between states, intergovernmental organizations also have the capacity to enter into treaties. The traditional view was that only states were subjects of international law, but with the founding of the United Nations, that view expanded to include intergovernmental organizations.
=== Mauveine === Mauveine was discovered when Henry Perkin was trying to convert an artificial base into the natural alkaloid quinine. He tried adding aniline – a different base with a simpler construction. This created a black product. After purification, drying and washing with alcohol, Perkin had a mauve dye. Perkin filed his patent in August 1856 and a new dye industry was born. He at first called his discovery Tyrian Purple evoking the value of the ancient, highly expensive, pigment. Other names include aniline purple and Perkin's mauve. Rather than one homogenous molecule, the original mauvine was primarily a mix of four major compounds, mauveine A, mauveine B, mauveine C, and mauveine B2, although there were other mauvine and pseudo mauveines in the dye product.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.